DOCKET NO.: C1039.70035US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Arthur M. Krieg

Serial No:

09/669,187

Confirmation. No.:

2999

Filed:

September 25, 2000

For:

IMMUNOSTIMULATORY NUCLEIC ACIDS

Examiner:

David J. Blanchard

Art Unit:

1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 29th day of January, 2004.

Maria A. Trevisan, Reg. No. 48,207

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

Information Disclosure Statement [X]

[X]PTO Form 1449 with cited references

Return Receipt Postcard [X]

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

> Respectfully submitted, Arthur M. Krieg, Applicant

Maria A. Trevisan, Reg. No. 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617)720-3500

Docket No. C1039.70035US00

Date: January 29, 2004

xNDDx

731436.1



DOCKET NO: C1039.70035US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

nt: Arthur M. Krieg

rial No: 09/669,187

Confirmation No:

2999

Filed:

September 25, 2000

For:

IMMUNOSTIMULATORY NUCLEIC ACIDS

Examiner:

David J. Blanchardl

Art Unit:

1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 29th day of January, 2004.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Serial No.: 09/669,187 - 2 - Art Unit: 1642

Conf. No.: 2999

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted, Arthur M. Krieg, Applicant

Maria A. Trevisan, Reg. No. 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2211

Telephone: (617) 720-3500

Docket No. C1039.70035US00

Date: January 29, 2004

xNDDx

		P. ''					
FORM PTO	ORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE			APPLICATION NO.: 09/669,187		ATTY. DOCKET NO.: C1039.70035US00	
				FILING DATE: September 25, 2000		CONFIRMATION NO.: 2999	
STAT	EMENT BY	APP	LICANT	APPLICANT:	Arthur M. Krieg		
Sheet	1	of	1	GROUP ART UNIT:	1642	EXAMINER: David J. Blanchard	

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite	U.S. Patent Doo	cument	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY	
	No.	Number	Kind Code			
		, ,,-			F	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
		Office/ Country	Number	Kind Code	(not necessary)	Cited Document MM-DD-YYYY	(Y/N)
	B36	wo	00/54803	A2	Panacea Pharmaceuticals, LLC	09-21-2000	
	B37	wo	00/75304	Al	Aventis Pasteur	12-14-2000	Abstract
			ļ		·		,
				-			
	 						t same
				:			-
			ļ				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.				
			Ti-			

EXAMINER	 DATE CONSIDERED	
	•	

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.